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The Coronavirus Disease 2019 (COVID-19) pandemic has affected over 165 million people and 
caused the death of 3.4 million worldwide (up to May 20, 2021) 
(https://coronavirus.jhu.edu/map.html), becoming a serious problem of global public health and 
the worst epidemic in the last century, after the pandemic 1918 influenza. Researchers 
worldwide are trying to find valuable drugs against the Severe Acute Respiratory Syndrome 
coronavirus 2 (SARS-CoV-2). Some of them focused as antivirals, others targeted in other ways 
(e.g. immunomodulation) to relieve the symptoms of the infected patients and help lower the 
death toll throughout the world. Unfortunately, there is a lack of effective drugs to manage 
COVID-19.  
 
The hopeful and long-awaited development of vaccines and the approval of their use in humans 
is a fact. The time consuming that it will take to achieve herd immunity due to waiting for the 
availability and distribution of the vaccines is a reality in full swing and shows significant health 
inequalities. Vaccines with up to 95% of efficacy and effectiveness have been developed and 
approved by the Food and Drug Administration (FDA), USA. Worldwide, 1.55 billion vaccine 
doses have been administered (up to May 20, 2021) (https://coronavirus.jhu.edu/map.html). 
However, it is unknown if the development of post-infection immunity detected confers 
medium-long term protection and the importance of mucosal immunity to protect against 
infection is still a matter of concern [1]. The effectiveness of a vaccine depends in part on its 
ability to induce a defensive immune response. Nevertheless, severe reactions have been 
observed in vaccine development for other respiratory viruses, including SARS-CoV [2], 
probably produced by vaccine-induced antibodies that facilitate viral replication [3]; or by a 










[4]. This reaction is of vital importance in the case of SARS-CoV-2 since the immune response 
in the form of a cytokine storm has been associated with severity [5]. 
 
A potential threat to patients with COVID-19 in helminths endemic areas (most of the tropical 
and subtropical areas of developing countries) is the systemic immunomodulatory effects of 
these parasites [6,7], through protein secretion [8] and by alteration of the intestinal microbiome 
[9], that may influence the severity of other infections. However, some authors consider this 
could be protective [10]. 
 
The possible implications of the immune-regulatory role of helminth intestinal infections in 
humans co-infected by SARS-CoV-2 and its effect on the viral disease outcome and COVID-19 
vaccines efficacy must be considered carefully using them in endemic helminth areas, in terms of 
more studies to understand this relationship. The individuals infected with helminths before 
being affected by SARS-CoV-2 are responding to the parasite infections by a specific Th2 type 
innate and adaptive immune responses. The Th2 pattern cytokines predominate in long-term 
helminth infected individuals [11]. The co-infected host needs to control the viral infection by a 
robust Th1 type lung microenvironment in the initial stages of SARS-CoV-2 [12]. Helminths 
modified intestinal microbiome can modulate host immune response. It is not well-defined if the 
interaction between helminth-microbiota will promote susceptibility or protection in the lungs. 
However, the generation of a tolerogenic and anti-inflammatory environment could stimulate 












In helminth-infected individuals, the immunomodulation of the innate and adaptive immune 
response characterized by a deviation to a Th2 pattern could enhance viral replication of SARS-
CoV-2 [11]. The significant case fatality rate caused by COVID-19, especially in certain 
countries, is produced by the uncontrolled innate immune response and destructive 
inflammation. Co-infections can modulate the host immunological outcome, and a range of 
responses can be observed during all clinical phases of COVID-19. The clinical resolution can be 
affected by different cofactors dependent on the virus, helminths, and the host, including their 
immunogenetic profile. Helminth co-infection might suppress the host immune responses and 
consequently could increase the severity of other infectious diseases, including COVID-19, and 
mitigate vaccine efficacy [4,5,11].  
 
Helminthiases are among the most common infectious diseases in developing countries and are 
in a synergistic epidemic, called syndemic [14,15]; several pathogens could infect individuals, 
and COVID-19-helminth syndemic in these areas may be a common possibility, not yet studied 
and understood enough [16]. The effects of these pathogens on COVID-19 vaccines efficacy 
must be considered during the current deployment of the mass use of COVID-19 vaccines in 
these endemic regions, ideally before. For instance, Schistosoma infections decrease the efficacy 
of vaccines against tuberculosis or tetanus (toxoid) [17]; lower levels of INF-γ and higher levels 
of IL-10 and TGF-β in individuals co-infected with Plasmodium, Ascaris lumbricoides, and 
hookworms, as compared to those infected only by Plasmodium, have been observed [18]; 
experimentally, in mice, helminth infections reduced the quantity and quality of antibody 
responses to vaccination against seasonal influenza [19], and diminished the strong immunity 












Before or concurrently with the mass use of COVID-19 vaccines in endemic helminth areas, 
public health strategic planning to decrease the helminth co-infection immunomodulatory effects 
must be studied. Massive deworming [6,15], or several boosts to induce a T-cell help response, 
and neutralizing antibodies as part of the adaptive immune response, such as immune-
modulating therapies [21], human monoclonal antibody blocking SARS-CoV-2 infection [22], 
and the use of a specific adjuvant [23] have been suggested. 
 
Schistosoma infection is correlated with increased transmission of HIV and deworming with 
decreased viral load, and improved CD4+ counts among HIV-infected individuals have been 
noted [15]. A single dose of 400 mg of albendazole before influenza immunization improved the 
immune response; the treated group had higher levels of total antibodies [24]. Deworming can 
decrease SARS-CoV-2 viral load and improve T cell CD8+ in the lung microenvironment [12]. 
Before implementing the COVID-19 vaccines, mass deworming could be a pharmacological 
intervention to improve anti-SARS-Cov-2 protection in helminth infected individuals, obviously 
requiring studies and confirmation yet. 
 
Due to its immunomodulatory, antioxidant, anti-inflammatory, and neuroprotective effects, 
melatonin is a potential complement or therapeutic alternative to combat viral, bacterial, and 
parasitic infections [25,26]. We coincide with the suggestion that this hormone should be 
considered for studies at prophylactic use or treatment alone or in combination with other drugs 
for COVID-19 to understand its usefulness in this context [27]. It has been demonstrated that 











equine encephalomyelitis virus [28]. Therefore, the use of this hormone before implementing 
programs of COVID-19 vaccination in helminths endemic areas should be studied since this 
pharmacological intervention would improve the immune impact of vaccines. Melatonin would 
be cheap and be an adjuvant during COVID-19 vaccination. 
 
The possible implications of the immune regulation caused by helminth intestinal infections in 
humans co-infected by SARS-CoV-2 are particularly worrisome in some countries of Latin 
America, such as is the case Venezuela, Honduras, Nicaragua, Peru, among others, since 
intestinal parasites constitute a serious and persistent public health problem in these nations. For 
example, along decades in Venezuela, it has been observed high rates of parasitic infection with 
one or more species, up to 92%, and rates of Ascaris lumbricoides and Trichuris trichiura up to 
74.6% and 82.8%, respectively, in impoverished communities [29-32].  
 
In the last two decades, the severe political, economic, and social crises in some countries have 
triggered an unprecedented increasing humanitarian crisis. That is especially the case of 
Venezuela. The rising trend of hyperinflation and food shortages have enhanced poverty and 
malnutrition rates; 96% of households are in poverty and 79% in extreme indigence. The 
malnutrition rate in children under five years of age from Venezuela is 8% [33]. This sequence 
of events and the collapse of health systems and public services foster the prevalence, 
transmission, and dynamic epidemiology of infectious agents. An increase in the prevalence of 
multiple infectious diseases, re-emergence of controlled illnesses such as tuberculosis, cholera, 











Venezuela the last two decades [34]. The whole immune balance status attributable to the 
immune interaction between host and pathogens must be defined in the current scenario.   
  
This complex epidemiological, sanitary, and poverty picture combined with the powerful 
transmissibility and eventual severity of the infection by SARS-CoV-2 indicate the significant 
risk of such populations suffering a more devastating impact of COVID-19 than people from 
other regions. According to family wealth, education, and ethnic group, substantial inequalities 
in the prevalence of infection have been revealed in developing and industrialized countries 
[35,36]. COVID-19 pandemic is beating Latin American countries with intensity. It is more 
complex at the poorest and disadvantaged groups [35]. Venezuela is currently the poorest 
country in this area and is ranked second in extreme poverty worldwide, only surpassed by 
Nigeria in Africa [33]. 
 
On the other hand, the several strategies that have been proposed to diminish helminths impact 
over viral vaccination are not feasible in Venezuela due to its current economic collapse. The 
situation in this country is incredibly distressing due to the collapse of the health systems, the 
scarcity of medicines and care policies for seniors and the impoverished. It is conceivable that 
COVID-19 morbidity and mortality in Venezuela could be high, and vaccines' immune impact is 
affected. In the current scenario of this country, COVID-19-helminth syndemic may be a joint 
likelihood, and the whole immune balance attributable to the immune interaction between host 
and pathogens must be resolved [6,10,37,38].     
 











infected by SARS-CoV-2 and its effects on the viral disease outcome and vaccination 
effectiveness raise high expectations and questions that need to be determined and open new 
avenues of investigation, particularly in tropical countries [6,10,37-40]. In conclusion, the 
implications of the immunomodulation effect of helminths in endemic areas must be considered 
in the context of COVID-19 mass vaccination. 
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